All News
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
#POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% responded after 3rd dose. Associated with longer Time of vaccine from last RTX & interestingly ultra dose 200mg used in the Netherlands @RheumNow https://t.co/TTXXtOU6vp
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
BRIDGE-PMR (rituximab in PMR) routine care extension to 52w
(in #PMRGCAJC one big qu asked was ?sustained benefit)
sustained benefit (RR 2.5 GC-free remission)
steroid-sparing (PNL 1.6g v 2.3g)
& ritux ?cheap enough now
but COVID calculus difficult
POS0269 #EULAR2022 @RheumNow https://t.co/Ln2ArclKO8 https://t.co/OtCwdjIPeL
David Liew drdavidliew ( View Tweet)
CorEvitas PsA Registry (1000+ pts)
Analysis of biologics prescription according to disease domains
No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL
Overall first line TNFi 40% > IL-17i 14%
POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
Aurelie Najm AurelieRheumo ( View Tweet)
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway RichardPAConway ( View Tweet)
Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
den Broeder et al. Follow-up to REDO study. Ultra-low dose RTX non-inferior for DAS28CRP. 1000mg 2.2 (2.0-2.4), 500mg 2.2 (2.1-2.4), 200mg 2.3 (2.2-2.5) (all given 6-monthly). Small effect by received dose though (0.15 per 1000mg) @RheumNow #EULAR2022 POS0652 https://t.co/hfSw9ndQpk
Richard Conway RichardPAConway ( View Tweet)
Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv
Richard Conway RichardPAConway ( View Tweet)
Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs
Richard Conway RichardPAConway ( View Tweet)
Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study
#EULAR2022
>CR https://t.co/AgBBuqYatW
ARD & RMD Open ARD_BMJ ( View Tweet)
Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S
Links:
Richard Conway RichardPAConway ( View Tweet)
A new finding - antimalarials improve safety w bDMARDs & #JAKi and reduce CV events and improve drug survival #Bestinclass. POS0242 @RheumNow @eular_org #EULAR2022 Neat. Safe, inexpensive and monitor eyes 👀 https://t.co/Ea4VA9vqwe
Janet Pope Janetbirdope ( View Tweet)
BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6
Janet Pope Janetbirdope ( View Tweet)
Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl
Richard Conway RichardPAConway ( View Tweet)
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis).
@RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
Robert B Chao, MD doctorRBC ( View Tweet)
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 OP0138:
BIOBADASER registry:
Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy
⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy
27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx
@Rheumnow https://t.co/nTuUooBmzV
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 ASAS/EULAR AxSpA Recs
⭐️Last: 2016
▶️All: education, exercise, 🚭
▶️❌csDMARD for axial disease
▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1
▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17
▶️Sustained remission: tapering of bDMARD "can be considered"
@RheumNow https://t.co/3yYU0Vb37r
Eric Dein ericdeinmd ( View Tweet)
OP0129 Eudravigilance eval pregnancies exposed to non-TNF biologics compared certolizumab. Possible signal w/#vendolizumab: 3 cases of corpus callosum agenesis (2 Crohn’s, 1 UC, 2 assc w/ other CNS malformations). Belim did not show consistent pattern #EULAR2022 @rheumnow https://t.co/BNKaxu6G0c
TheDaoIndex KDAO2011 ( View Tweet)
